Valuation : Nanobiotix

Market Cap 1.58B 1.84B 1.49B 1.35B 2.54B 175B 2.55B 17.62B 6.81B 88.97B 6.89B 6.74B 282B P/E 2026 *
-75.8x
P/E 2027 * -131x
Enterprise Value 1.63B 1.89B 1.53B 1.39B 2.61B 180B 2.62B 18.14B 7.01B 91.56B 7.09B 6.94B 290B EV / Sales 2026 *
42.7x
EV / Sales 2027 * 38.7x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day-4.18%
1 week-11.58%
Current month-10.26%
1 month-6.93%
3 months+8.12%
6 months-7.04%
Current year+59.69%
1 week 30
Extreme 30
34.32
1 month 30
Extreme 30
39.98
Current year 16.66
Extreme 16.66
47.66
1 year 7.92
Extreme 7.92
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 2009-11-15
Director of Finance/CFO 54 2021-05-31
Chief Tech/Sci/R&D Officer 68 2023-09-04
Director TitleAgeSince
Director/Board Member 76 2011-06-22
Director/Board Member 65 2013-12-31
Director/Board Member 57 2014-06-17
Date Insider Type Main position Quantity % Market Cap. Importance
7/17/26 Buy

Chairman

598 0.0012%
7/17/26 Buy

Chairman

598 0.0012%
7/16/26 Buy

Chairman

6,114 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
-4.18%-11.58%+295.18%+250.68% 1.84B
-3.24%-7.78%-5.35%+11.20% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
-0.37%-2.53%+10.91%+30.93% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average -1.37%-3.75%+94.95%+126.66% 26.88B
Weighted average by Cap. -1.04%-3.10%+86.94%+133.93%

Financials

2026 *2027 *
Net sales 38.06M 44.23M 35.84M 32.66M 61.1M 4.21B 61.34M 425M 164M 2.14B 166M 162M 6.79B 42.83M 49.77M 40.33M 36.74M 68.75M 4.74B 69.02M 478M 185M 2.41B 187M 183M 7.64B
Net income -12.18M -14.15M -11.46M -10.45M -19.55M -1.35B -19.62M -136M -52.52M -686M -53.13M -51.98M -2.17B -52.44K -60.94K -49.38K -44.99K -84.18K -5.8M -84.51K -585K -226K -2.95M -229K -224K -9.36M
Net Debt 46M 53.46M 43.31M 39.46M 73.84M 5.09B 74.13M 513M 198M 2.59B 201M 196M 8.21B 76.4M 88.79M 71.94M 65.55M 123M 8.45B 123M 853M 330M 4.3B 333M 326M 13.64B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
26-09-09 €31.14 -4.18% 248,326
26-09-08 €32.50 -1.99% 100,688
26-09-07 €33.16 -1.01% 120,152
26-09-04 €33.50 -1.93% 122,004
26-09-03 €34.16 -3.01% 96,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.14EUR
Average target price
52.20EUR
Spread / Average Target
+67.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!